Beyond miR-122: Identification of microRNA alterations in blood during a time course of hepatobiliary injury and biliary hyperplasia in rats

Toxicological Sciences

Volumn 150, Issue 1, 2016, Pages 3-14

  Church, Rachel J ^a   Otieno, Monicah ^b   McDuffie, James Eric ^b   Singh, Bhanu ^b   Sonee, Manisha ^b   Hall, LeRoy ^b   Watkins, Paul B ^a   Ellinger Ziegelbauer, Heidrun ^c   Harrill, Alison H ^a,d  

^a Hamner UNC Institute for Drug Safety Sciences   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Biliary hyperplasia; Biomarkers; Drug induced liver injury; Hepatobiliary injury; MiRNA

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; 1 [4 (4 FLUOROPHENYL) 2,6 DIISOPROPYL 5 PROPYLPYRIDIN 3 YL]ETHANOL; ALCOHOL DERIVATIVE; MICRORNA 122; MICRORNA 192; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MICRORNA; MIRN122 MICRORNA, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY HYPERPLASIA; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EPITHELIUM CELL; HEPATOBILIARY DISEASE; HEPATOBILIARY INJURY; LIVER NECROSIS; MALE; NONHUMAN; RAT; RNA ANALYSIS; ANIMAL; BLOOD; DISEASE MODEL; HEPATOBILIARY SYSTEM; HYPERPLASIA; LIVER; PATHOLOGY; SPRAGUE DAWLEY RAT; TOXIC HEPATITIS;

1-NAPHTHYLISOTHIOCYANATE; ANIMALS; BILIARY TRACT; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DISEASE MODELS, ANIMAL; HYPERPLASIA; LIVER; MALE; MICRORNAS; RATS, SPRAGUE-DAWLEY;

EID: 84963812354     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv260     Document Type: Article

References (31)

1. Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
2. Church, R. J., McDuffie, J. E., Sonee, M., Otieno, M., Ma, J. Y., Liu, X., Watkins, P. B., and Harrill, A. H. (2014). MicroRNA-34c-3p is an early predictive biomarker for doxorubicin-induced glomerular injury progression in male Sprague-Dawley rats. Toxicol. Res. 3, 384-394.
3. Cullen, J. M., Falls, J. G., Brown, H. R., Yoon, L. W., Cariello, N. F., Faiola, B., Kimbrough, C. L., Jordan, H. L., and Miller, R. T. (2010). Time course gene expression using laser capture microscopy- extracted bile ducts, but not hepatic parenchyma, reveals acute alpha-naphthylisothiocyanate toxicity. Toxicol. Pathol. 38, 715-729.
4. Dear, J. W., Antoine, D. J., Starkey-Lewis, P., Goldring, C. E., and Park, B. K. (2014). Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. Br. J. Clin. Pharmacol. 77, 904-905.
5. Ellinger-Ziegelbauer, H., Adler, M., Amberg, A., Brandenburg, A., Callanan, J. J., Connor, S., Fountoulakis, M., Gmuender, H., Gruhler, A., Hewitt, P., et al. (2011). The enhanced value of combining conventional and "omics" analyses in early assessment of drug-induced hepatobiliary injury. Toxicol. Appl. Pharmacol. 252, 97-111.
6. Fang, L., Ellims, A. H., Moore, X. L., White, D. A., Taylor, A. J., Chin-Dusting, J., and Dart, A. M. (2015). Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J. Transl. Med. 13, 314.
7. Filipowicz, W., and Grosshans, H. (2011). The liver-specific microRNA miR-122: biology and therapeutic potential. Prog. Drug Res. 67, 221-238.
8. Hand, N. J., Master, Z. R., Eauclaire, S. F., Weinblatt, D. E., Matthews, R. P., and Friedman, J. R. (2009). The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 136, 1081-1090.
9. Harrill, A. H., Roach, J., Fier, I., Eaddy, J. S., Kurtz, C. L., Antoine, D. J., Spencer, D. M., Kishimoto, T. K., Pisetsky, D. S., Park, B. K., et al. (2012). The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin. Pharmacol. Therap. 92, 214-220.
10. Kanki, M., Moriguchi, A., Sasaki, D., Mitori, H., Yamada, A., Unami, A., and Miyamae, Y. (2014). Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats. Toxicology 324, 158-168.
11. Kossor, D. C., Meunier, P. C., Handler, J. A., Sozio, R. S., and Goldstein, R. S. (1993). Temporal relationship of changes in hepatobiliary function and morphology in rats following alpha- naphthylisothiocyanate (ANIT) administration. Toxicol. Appl. Pharmacol. 119, 108-114.
12. Krauskopf, J., Caiment, F., Claessen, S. M., Johnson, K. J., Warner, R. L., Schomaker, S. J., Burt, D. A., Aubrecht, J., and Kleinjans, J. C. (2015). Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for druginduced liver injury. Toxicol. Sci. 143, 268-276.
13. Kroh, E. M., Parkin, R. K., Mitchell, P. S., and Tewari, M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRTPCR). Methods 50, 298-301.
14. Linsen, S. E., de Wit, E., de Bruijn, E., and Cuppen, E. (2010). Small RNA expression and strain specificity in the rat. BMC Genomics 11, 249.
15. Momen-Heravi, F., Bala, S., Kodys, K., and Szabo, G. (2015). Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. Sci. Rep. 5, 9991.
16. Nassirpour, R., Mathur, S., Gosink, M. M., Li, Y., Shoieb, A. M., Wood, J., O'Neil, S. P., Homer, B. L., and Whiteley, L. O. (2014). Identification of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and qPCRbased profiling platforms. BMC Genomics 15, 485.
17. Pavkovic, M., Riefke, B., and Ellinger-Ziegelbauer, H. (2014). Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury. Toxicology 324, 147-157.
18. Pavkovic, M., Riefke, B., Frisk, A. L., Groticke, I., and Ellinger- Ziegelbauer, H. (2015). Glomerulonephritis-induced changes in urinary and kidney microRNA profiles in rats. Toxicol. Sci.145, 348-359.
19. Pek, S. L., Tavintharan, S., Woon, K., Lin, L., Ong, C. N., Lim, S. C., and Sum, C. F. (2015). MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation. Exp. Biol. Med. (Maywood). (Forthcoming). http://www.ncbi.nlm.nih.gov/ pubmed/26429200. Accessed December 12, 2015.
20. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675.
21. Starkey Lewis, P. J., Dear, J., Platt, V., Simpson, K. J., Craig, D. G., Antoine, D. J., French, N. S., Dhaun, N., Webb, D. J., Costello, E. M., et al. (2011). CirculatingmicroRNAs as potentialmarkers of human drug-induced liver injury. Hepatology 54, 1767-1776.
22. Stevens, J. L., and Baker, T. K. (2009). The future of drug safety testing: expanding the view and narrowing the focus. Drug Disc. Today 14, 162-167.
23. Tan, Y., Ge, G., Pan, T., Wen, D., and Gan, J. (2015). Serum MiRNA panel as potential biomarkers for chronic hepatitis B with persistently normal alanine aminotransferase. Clin. Chim. Acta 451, 232-239.
24. Tanaka, T., Haneda, S., Imakawa, K., Sakai, S., and Nagaoka, K. (2009). A microRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. Differentiation 77, 181-187.
25. Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., and Galas, D.J. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl Acad. Sci. U. S. A. 106, 4402-4407.
26. Ward, J., Kanchagar, C., Veksler-Lublinsky, I., Lee, R. C., McGill, M. R., Jaeschke, H., Curry, S. C., and Ambros, V. R. (2014). Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc. Natl Acad. Sci. U. S. A. 111, 12169-12174.
27. Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., Galas, D. J., and Wang, K. (2010). The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733-1741.
28. Xiao, Y., Wang, J., Chen, Y., Zhou, K., Wen, J., Wang, Y., Zhou, Y., Pan, W., and Cai, W. (2014). Up-regulation of miR-200b in biliary atresia patients accelerates proliferation and migration of hepatic stallate cells by activating PI3K/Akt signaling. Cell. Signal. 26, 925-932.
29. Yamaura, Y., Nakajima, M., Takagi, S., Fukami, T., Tsuneyama, K., and Yokoi, T. (2012). Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One 7, e30250.
30. Zahm, A. M., Hand, N. J., Boateng, L. A., and Friedman, J. R. (2012). Circulating microRNA is a biomarker of biliary atresia. J. Pediatr. Gastroenterol. Nutr. 55, 366-369.
31. Zhao, X., Wang, K., Liao, Y., Zeng, Q., Li, Y., Hu, F., Liu, Y., Meng, K., Qian, C., Zhang, Q., et al. (2015). MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFbetaRI on cardiac fibroblasts. Cell. Physiol. Biochem. 35, 213-226.